Medoril (Calcium Dobesilate)

Calcium dobesilate reduces the permeability of capillaries and strengthens endothelial cells, which limits fluid extravasation. It also exhibits anti‑inflammatory and antioxidant actions, thereby improving microvascular blood flow and protecting tissues from oxidative stress. These combined effects support better venous return and retinal vessel stability.

The dosage of Medoril is determined by the prescribing clinician based on the individual’s condition, severity and overall health status. Physicians tailor the regimen to achieve optimal therapeutic benefit while minimizing potential adverse effects. Patients should follow the exact dosing instructions provided by their healthcare professional.

Safety data for calcium dobesilate in pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate the clinical situation and discuss alternatives before prescribing Medoril to pregnant or nursing women.

To request Medoril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Medoril’s active ingredient, calcium dobesilate, offers a dual action of reducing capillary permeability and providing antioxidant protection. Compared with other vasoprotective agents such as flavonoid‑based preparations, calcium dobesilate has a distinct mechanism that directly stabilises endothelial cells, which may result in more consistent improvement of microcirculatory function in the indicated conditions.

Medoril should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging to protect them from moisture and direct sunlight. Do not refrigerate or freeze the product, as temperature extremes could affect its stability and efficacy.

Medoril is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional. Administration can be with or without food, depending on the prescriber’s recommendation and the patient’s tolerance.

The most serious risks include severe allergic reactions such as anaphylaxis, hepatic dysfunction indicated by elevated liver enzymes, and hematologic abnormalities like thrombocytopenia or neutropenia. Patients should seek immediate medical attention if they experience symptoms such as rash, swelling, jaundice, unexplained bruising or a sudden drop in blood counts.

Medoril is contraindicated in individuals with known hypersensitivity to calcium dobesilate or any of the tablet’s excipients. Patients with severe liver disease, uncontrolled bleeding disorders, or those currently receiving high‑dose anticoagulant therapy should avoid the medication unless a physician determines that the benefits outweigh the risks.